Cargando…
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
The combination of cytotoxic treatment with strategies for immune activation represents an attractive strategy for tumour therapy. Following reduction of high tumour burden by effective cytotoxic agents, two major immune-stimulating approaches are being pursued. First, innate immunity can be activat...
Autores principales: | Gassner, Franz Josef, Weiss, Lukas, Geisberger, Roland, Hofbauer, Josefina Piñón, Egle, Alexander, Hartmann, Tanja Nicole, Greil, Richard, Tinhofer, Inge |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3029666/ https://www.ncbi.nlm.nih.gov/pubmed/20857100 http://dx.doi.org/10.1007/s00262-010-0920-3 |
Ejemplares similares
-
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
por: Egle, Alexander, et al.
Publicado: (2018) -
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015) -
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells
por: Zaborsky, Nadja, et al.
Publicado: (2016) -
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia
por: Brachtl, Gabriele, et al.
Publicado: (2013) -
The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells
por: Hofbauer, Sebastian W., et al.
Publicado: (2015)